Synergistic association of PTGS2 and CYP2E1 genetic polymorphisms with lung cancer risk in northeastern Chinese

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Guo, Shujie ^a   Li, Xiaobo ^a   Gao, Min ^b   Kong, Hong ^a   Li, Yuqiong ^a   Gu, Mingliang ^c   Dong, Xiaoqun ^d   Niu, Wenquan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; CYP2E1 GENE; DRINKING; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PTGS2 GENE; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING;

AGED; CASE-CONTROL STUDIES; CHINA; CYCLOOXYGENASE 2; CYTOCHROME P-450 CYP2E1; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 84862687893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039814     Document Type: Article

References (27)

1. Brennan P, Hainaut P, Boffetta P, (2011) Genetics of lung-cancer susceptibility. Lancet Oncol 12: 399-408.
2. Subramanian J, Govindan R, (2008) Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 9: 676-682.
3. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, et al. (2011) Personalized treatment of lung cancer. Semin Oncol 38: 274-283.
4. Zhan P, Wang J, Zhang Y, Qiu LX, Zhao SF, et al. (2010) CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians. Lung Cancer 69: 19-25.
5. Smith WL, Langenbach R, (2001) Why there are two cyclooxygenase isozymes. J Clin Invest 107: 1491-1495.
6. Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P, (2001) Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 86: 5615-5619.
7. Mineo TC, Ambrogi V, Cufari ME, Pompeo E, (2010) May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma? Eur J Cardiothorac Surg 38: 245-252.
8. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, et al. (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001.
9. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, et al. (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764.
10. Micu AL, Miksys S, Sellers EM, Koop DR, Tyndale RF, (2003) Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. J Pharmacol Exp Ther 306: 941-947.
11. Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, et al. (2009) Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. J Toxicol Environ Health B Crit Rev 12: 362-388.
12. Haque AK, Au W, Cajas-Salazar N, Khan S, Ginzel AW, et al. (2004) CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study. Appl Immunohistochem Mol Morphol 12: 315-322.
13. Michaud V, Frappier M, Dumas MC, Turgeon J, (2010) Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One 5: e15666.
14. Niu W, Zhang Y, Ji K, Gu M, Gao P, et al. (2010) Confirmation of top polymorphisms in hypertension genome wide association study among Han Chinese. Clin Chim Acta 411: 1491-1495.
15. Stram DO, Leigh Pearce C, Bretsky P, Freedman M, Hirschhorn JN, et al. (2003) Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 55: 179-190.
16. Pattin KA, White BC, Barney N, Gui J, Nelson HH, et al. (2009) A computationally efficient hypothesis testing method for epistasis analysis using multifactor dimensionality reduction. Genet Epidemiol 33: 87-94.
17. Hahn LW, Ritchie MD, Moore JH, (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19: 376-382.
18. Cardon LR, Bell JI, (2001) Association study designs for complex diseases. Nat Rev Genet 2: 91-99.
19. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, et al. (2008) Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 5: e185.
20. Tang K, Li Y, Zhang Z, Gu Y, Xiong Y, et al. (2010) The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies. BMC Cancer 10: 575.
21. Peng WJ, He Q, Yang JX, Wang BX, Lu MM, et al. (2011) Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep.
22. Pankratz VS, Sun Z, Aakre J, Li Y, Johnson C, et al. (2011) Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer. J Thorac Oncol 6: 1488-1495.
23. Liao Z, Milas L, (2004) COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer. Expert Rev Anticancer Ther 4: 543-560.
24. Liu F, He Y, Peng X, Wang W, Yang X, (2010) Association of the 8473T>C cyclooxygenase-2 (COX-2) gene polymorphism with lung cancer risk in Asians. Asian Pac J Cancer Prev 11: 1257-1262.
25. Wang Y, Yang H, Li L, Wang H, Zhang C, et al. (2010) Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer 46: 758-764.
26. Moore JH, (2010) Detecting, characterizing, and interpreting nonlinear gene-gene interactions using multifactor dimensionality reduction. Adv Genet 72: 101-116.
27. Koch A, Gustafsson B, Fohlin H, Sorenson S, (2011) Cyclooxygenase-2 expression in lung cancer cells evaluated by immunocytochemistry. Diagn Cytopathol 39: 188-193.